

Special Issue

Breast Cancers Treatments: Overcoming Drug Resistance

Message from the Guest Editors

The scope of this Special Issue provides a platform to all researchers in the field of breast cancer to present their work in elucidating the mechanisms that lead to drug resistance, as well as the drugs or combinations of drugs that are under development to address this resistant mechanism. The research could encompass basic and translational studies involving various bio-informatic avenues confirmed by wet lab experiments. It is preferable that the proposed work addresses mechanisms with novel approaches, which could result in clinical trials leading to therapy. The work could involve genetic, epigenetic, genomic, or proteomic studies that are well substituted and complemented by confirmatory experiments with statistical significance.

Guest Editors

Dr. Eswar Shankar

Medical Oncology Division, Department of Internal Medicine, Wexner Medical Center, Ohio State University, 420 W 12th Ave, Columbus, OH 43210, USA

Dr. Balaji Chandrasekaran

Rangel College of Pharmacy, Texas A&M University, College Station, TX 77843, USA

Deadline for manuscript submissions

closed (1 December 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/161215

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)